This filing is routine governance — no material change to the business outlook. Monitor the company's cash burn and pipeline progress (clinical-stage biotech) for future equity needs. The evergreen provision signals management's intent to use equity as a compensation tool, but actual dilution will depend on future grant rates and stock price.
Price Chart
Executive Summary
Inmune Bio held its 2026 annual meeting and shareholders approved an amendment to the 2021 Stock Incentive Plan, increasing the authorized share pool from 6,500,000 to 9,158,525 shares and adding an evergreen provision. All director nominees were elected and the auditor was ratified. This is a routine governance filing that authorizes additional equity incentive capacity but does not change the operational or financial outlook of the company.
Key Facts
- Shareholders approved the Third Amended and Restated 2021 Stock Incentive Plan, increasing authorized shares from 6,500,000 to 9,158,525.
- An evergreen provision was added: on the first trading day of each year from 2027 to 2031, the reserve will automatically increase by the lesser of 10% of outstanding shares or a board-determined amount.
- All five director nominees were elected (David Moss, J. Kelly Ganjei, Tim Schroeder, Scott Juda, Marcia Allen).
- CBIZ CPAs P.C. was ratified as independent auditor for FY2026 with 17,293,255 votes for and 107,064 against.
- Approval of the stock plan passed with 6,085,086 for, 2,775,224 against, and 95,367 abstentions (broker non-votes: 8,501,317).
Financial Impact
No immediate financial impact. The plan amendment increases the equity incentive pool by ~2.66M shares (from 6.5M to 9.16M). At the current $34M market cap, this represents potential dilution of up to ~$5-6M if all new shares were granted at today's price, but the dilution is contingent on future grants and vesting.
Risk Factors
- Potential future dilution as the evergreen provision allows for automatic share increases.
- Shareholder opposition was notable: ~31% of votes cast (excluding brokers) were against the plan amendment.
- Clinical-stage biotech with $34M market cap faces execution risk on pipeline and financing needs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-069611 |
| Document: ea0295129-8k_inmune.htm | 0001213900-26-069611 |
| Document: 0001213900-26-069611-index-headers.html | 0001213900-26-069611 |
| Document: 0001213900-26-069611-index.html | 0001213900-26-069611 |
| Document: 0001213900-26-069611.txt | 0001213900-26-069611 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $1.61 | awaiting T+60 | — | $1.46 (−9.32%) |
Sep 16, 2026 5w ago | 3 | $2.18 | awaiting T+60 | — | $1.46 (−33.03%) |
Jul 9, 2026 15w ago | Press Release | $1.79 $1.93 | ▲ +7.82% | ▲ +6.19% | $1.46 (−18.44%) |
Jul 1, 2026 16w ago | 8-K | $1.68 | awaiting T+60 | — | $1.46 (+13.10%) |
Jun 23, 2026 17w ago | 8-K | $1.35 | awaiting T+60 | — | $1.46 (+8.15%) |
Jun 17, 2026 18w ago | 8-K | $1.45 | awaiting T+60 | — | $1.46 (+0.69%) |
Jun 2, 2026 20w ago | 8-K | $1.32 $2.40 | ▲ +81.82% | ▲ +79.32% | $1.46 (+10.61%) |
May 7, 2026 24w ago | Press Release | $1.43 $1.91 | ▲ +33.57% | ▲ +28.73% | $1.46 (+2.10%) |
May 5, 2026 24w ago | 8-K | $1.52 $1.75 | ▲ +15.13% | ▲ +13.07% | $1.46 (−3.95%) |
Apr 30, 2026 25w ago | Press Release | $1.43 | awaiting T+60 | — | $1.46 (+2.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers